ES2174103T3 - Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano. - Google Patents

Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.

Info

Publication number
ES2174103T3
ES2174103T3 ES96931040T ES96931040T ES2174103T3 ES 2174103 T3 ES2174103 T3 ES 2174103T3 ES 96931040 T ES96931040 T ES 96931040T ES 96931040 T ES96931040 T ES 96931040T ES 2174103 T3 ES2174103 T3 ES 2174103T3
Authority
ES
Spain
Prior art keywords
human mammary
cells
wap
regulatory sequences
direct expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96931040T
Other languages
English (en)
Inventor
Walter H Gunzburg
Robert Michael Saller
Brian Salmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Austrian Nordic Biotherapeutics AG
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Austrian Nordic Biotherapeutics AG
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austrian Nordic Biotherapeutics AG, Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Austrian Nordic Biotherapeutics AG
Application granted granted Critical
Publication of ES2174103T3 publication Critical patent/ES2174103T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE WAP O DE SECUENCIAS REGULADORAS DE VTMR PARA LA EXPRESION DIRIGIDA DE SECUENCIAS UNIDAS DE ADN HETEROLOGO EN CELULAS MAMARIAS HUMANAS, INCLUIDAS LAS CELULAS DEL CARCINOMA DE MAMA HUMANO.
ES96931040T 1995-09-06 1996-09-06 Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano. Expired - Lifetime ES2174103T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK97695 1995-09-06

Publications (1)

Publication Number Publication Date
ES2174103T3 true ES2174103T3 (es) 2002-11-01

Family

ID=8099620

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96931040T Expired - Lifetime ES2174103T3 (es) 1995-09-06 1996-09-06 Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.

Country Status (9)

Country Link
US (1) US20050019307A1 (es)
EP (1) EP0848757B1 (es)
JP (1) JPH11511979A (es)
AT (1) ATE214101T1 (es)
AU (1) AU6987696A (es)
DE (1) DE69619683T2 (es)
DK (1) DK0848757T3 (es)
ES (1) ES2174103T3 (es)
WO (1) WO1997009440A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3908274B2 (ja) 1995-03-09 2007-04-25 ゲーエスエフ−フォルシュンクスツェントラム・フュア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー 遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター
DK0835137T3 (da) 1995-06-27 2006-03-06 Bavarian Nordic As Indkapslede celler, som danner viruspartikler
US7074398B1 (en) 1995-10-13 2006-07-11 Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh Retroviral vectors carrying senescent cell derived inhibitors 1 (SDI-1)or antisense SDI-1 nucleotide sequences
SI0892852T1 (sl) * 1996-03-27 2006-04-30 Bavarian Nordic As Inkapsulirane celice, ki eksprimirajo citokrom P450 za aktiviranje predzdravila
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
ATE278029T1 (de) 1998-01-06 2004-10-15 Inst Virologie Teilrechtsfaehi Rekonstituierender retroviraler vektor (recon vektor) für gezielte genexpression
DE19903371C1 (de) * 1999-01-28 2000-06-15 Mice & More Gmbh & Co Kg Säugetier sowie Verfahren zu seiner Herstellung und seine Verwendung
MXPA05000778A (es) * 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
CN101955523B (zh) * 2010-03-10 2014-06-25 中国科学院海洋研究所 一种具抑菌活性的中华绒螯蟹乳清酸蛋白的制备及应用
AU2018239428A1 (en) * 2017-03-21 2019-10-17 PharmaCyte Biotech, Inc. Encapsulated cells producing cytochrome P450 and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
WO1995015334A1 (en) * 1993-11-30 1995-06-08 California Pacific Medical Center Research Institute cDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT

Also Published As

Publication number Publication date
US20050019307A1 (en) 2005-01-27
JPH11511979A (ja) 1999-10-19
DK0848757T3 (da) 2002-07-01
WO1997009440A1 (en) 1997-03-13
EP0848757B1 (en) 2002-03-06
DE69619683D1 (de) 2002-04-11
ATE214101T1 (de) 2002-03-15
DE69619683T2 (de) 2002-09-26
AU6987696A (en) 1997-03-27
EP0848757A1 (en) 1998-06-24

Similar Documents

Publication Publication Date Title
ES2187497T3 (es) Promotores preferentemente en tejidos.
ES2192301T3 (es) Derivados de resorcinol.
DE3885317D1 (de) Makromolekulare Platin-Antitumorverbindungen.
AR026994A1 (es) Nuevas construcciones de expresion en plantas.
ATE336229T1 (de) Zusammensetzung auf der basis polymerer mizellen
ES2145451T3 (es) Secuencia de dna y proteina de cancer de mamas codificada especifica para mamas.
NL7802695A (nl) Massagegordel om te dragen in de buurt van de lendewervelkolom bij de mens.
DE59611341D1 (de) Verwendung von saccharid-konjugaten
NO934130D0 (no) Tumoravvisningsantigenforl!pere, tumoravvisningsantigenersamt anvendelse derav
TR200102191T2 (tr) HER-2/neu füzyon proteinleri.
SE8501709D0 (sv) Improvements in or relating to intrleukin therapy
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
ES2174103T3 (es) Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
ES2189992T3 (es) Reduccion del crecimiento del pelo.
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
ES2175231T3 (es) Nuevas anfetaminas activadas.
ES2123996T3 (es) Analogos de 7-etertaxol, uso antineoplasico y composiciones farmaceuticas que los contienen.
EP1667716A4 (en) CYTOTOXICITY ASSAY OF CELLS WITH ADVICE ON SURFACE EXPRESSION OF CD44
PA8492701A1 (es) Derivados de resorcinol.
ES2136583T1 (es) Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa.
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
TR199802300T2 (xx) �nsan G proteini �3 alt-birimindeki bir gendeki genetik d�n���m�n hastal�klar�n te�hisi i�in kullan�lmas�.
ATE311399T1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
IT8025572A0 (it) Pennarello. stoppino di scrittura in fibra per
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 848757

Country of ref document: ES